Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B | P35368 | 3/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | WDR5 | P61964 | 6/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113723 | 0.94 | CHRM2 (0.44) | ADRA1BADRA1DADRA1ACHRM2CHRM3 | |
| SCHEMBL115051 | 0.90 | ADRA1D (0.43) | ADRA1BADRA1DADRA1ACHRM2CHRM3 | |
| SCHEMBL114794 | 0.90 | CXCR3 (0.45) | ADRA1BADRA1DADRA1ACHRM2CHRM3 | |
| SCHEMBL115763 | 0.88 | ADRA1B (0.41) | ADRA1BADRA1DADRA1ACHRM2CHRM3 | |
| SCHEMBL114109 | 0.88 | ADRA1B (0.42) | ADRA1BADRA1DADRA1ACHRM2CHRM3 | |
| SCHEMBL113544 | 0.86 | ADRA1B (0.45) | ADRA1BADRA1DADRA1ACHRM2CHRM3 | |
| SCHEMBL114108 | 0.85 | ADRA1B (0.42) | ADRA1BADRA1DADRA1ACHRM2CHRM3 | |
| SCHEMBL3739637 | 0.83 | THRB (0.44) | GRM5 | |
| SCHEMBL168743 | 0.80 | CXCR3 (0.58) | WDR5GRIN2BGRM5 | |
| SCHEMBL168466 | 0.80 | THRB (0.45) | CHRM2CHRM3GRIN2BGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | claimed |
| EP-2424840-B1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2424840-B1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2424840-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126811-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126811-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | ADRA1B 147/4885ADRA1D 160/4885ADRA1A 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.